NewsRx

Search our medical news database

Ciphergen Biosystems, Inc.

Researchers find peptide biomarkers effective in early diagnosis of Alzheimer

Published in Physician Law Weekly, August 18th, 2004

Ciphergen Biosystems, Inc., (NASDAQ:CIPH) announced that three separate studies involving a SELDI ProteinChip Amyloid Beta (A-beta) Multi-Peptide Immunoassay were presented during a biomarkers symposium.

The presentations took place at the 9th International Conference on Alzheimer's Disease (ICAD) in Philadelphia.

The first study presented by Dr. Nicolas Sergeant from INSERM in France entitled "Amino-truncated A-beta 42 species as early diagnostic and etiological biomarkers of Alzheimer disease" described using a SELDI immunoassay to evaluate the presence of N-terminally truncated Abeta42 peptides in patient cerebrospinal fluid (CSF).

...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Law Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook